Bimekizumab is the first dual targeting IL‐17A/F antibody, and the 16‐week American College of Rheumatology 50% improvement rate (ACR50) in TNF‐α inhibitor‐refractory psoriatic arthritis was 46% in one study [217]. Here, TNF is linked to psoriatic arthritis.